Results of Meeting
Released
Released
Announcement PDF
ASX Announcement
05/03/2021
Results of General Meeting
Perth, Australia; 5 March 2021: Emyria Limited (ASX:EMD, “Emyria” or the “Company”) advises
that a General Meeting of shareholders was held today, 5th March 2021.
All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule
3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll
results and the proxies received in respect of each resolution are set out below:
Poll Results
Resolutions
For
Against
Abstain
1
Ratification of prior
issue of Placement
Shares
97,344,757
110,000
258,607
2
Ratification of prior
issue of Placement
Options
97,344,757
120,000
258,607
3
Ratification of prior
issue of Lead Manager
Options to Sixty Two
Capital Pty Ltd
97,073,394
110,000
529,970
4
Ratification of prior
issue of Consultant
Options to Professor
Bruce Robinson
97,095,775
0
617,589
1
Proxy Votes Received
Resolutions
For
Against
At Proxy
Holders
Discretion
Abstain
1
Ratification of prior
issue of Placement
Shares
96,556,223
110,000
237,935
258,607
2
Ratification of prior
issue of Placement
Options
96,546,223
120,000
237,935
258,607
3
Ratification of prior
issue of Lead
Manager Options to
Sixty Two Capital
Pty Ltd
96,284,860
110,000
237,935
529,970
4
Ratification of prior
issue of Consultant
Options to
Professor Bruce
Robinson
96,307,241
0
237,935
617,589
Release authorised by:
Simon Robertson
Company Secretary
2
For further information:
Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Media/Investor Relations
+61 (0) 404 577 076
lexi@janemorganmanagement.com.au
Andrew Williams
Media Relations
+61 (0) 412 614 125
andreww@profilemedia.com.au
About Emyria (www.emyria.com)
Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target
unmet needs and are focused on obtaining approval from major global regulators. Emyria’s
drug development programs are informed by insights generated from extensive analysis of
Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across
Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au)
Emyria Data provides deep treatment insights and is therefore a source of unique IP,
strategically designed drug development and personalised care programs.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company,
the company’s strategy, future operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements.
Actual results may differ materially from those indicated by such forward-looking statements as a
result of various important factors, including: the Company’s ability to successfully develop its product
candidates and timely complete its planned clinical programs and the Company’s ability to obtain
marketing approvals for its product candidates. In addition, the forward-looking statements included
in this press release represents the Company’s views as of the date hereof. The Company anticipates
that subsequent events and developments will cause the Company’s views to change. However, while
the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not
be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
3
Share your feedback
Discover